Latest / Decera Clinical Education Oncology Podcast
Targeted Treatment Options for Patients With AML and FLT3 or IDH1/2 Mutations
In this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses targeted therapy with FLT3 and IDH1/2 inhibitors in AML, with a focus on the nursing perspective. Topics include:
Approved and emerging treatment options for FLT3-mutated AML
Management of adverse events associated with FLT3 inhibitors
Therapies for IDH1- and IDH2-mutated AML
Identifying and managing differentiation syndrome associated with IDH1/2 inhibitors
Presenters:
Sarah M. Tinsley, PhD, APRN, AOCN
Nurse Practitioner
Courtesy Assistant Professor
Department of Malignant Hematology
Moffitt Cancer Center
University of…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.